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Abstract   
Aim: To characterise the numbers of reagent strips dispensed for self monitoring of 
blood glucose (SMBG) to patients with type 2 diabetes in Tayside, Scotland, in 1993, 
1999 and 2009. Methods: A diabetes clinical information system in Tayside record-
linked to electronic dispensed prescribing records, was used to collate all dispensed 
prescribing records for three cross-sectional samples of patients with type 2 diabetes 
in 1993 (n=5,728), 1999 (n=8,109), and January 1
st
 2009 (n=16,450). The numbers of 
reagent strips dispensed during the relevant calendar year were calculated, and 
patients stratified by treatment. We also explored whether age, sex or material and 
social deprivation were associated with whether a patient received strips. Results: 
Proportions of people who received SMBG reagent strips increased from 15.5% in 
1993, to 24.2% in 1999 to 29.8% in 2009, as did numbers of strips dispensed. While 
the proportion of diet-treated patients who received reagent strips was still very low in 
2009 (5.6%), the proportion among those treated with oral agents tripled from 9.4% to 
27.4% between1993-2009. Over 90% of patients treated with insulin received reagent 
strips, and among non-insulin-treated patients this was commoner among women, 
younger people and less deprived groups. Conclusions: The numbers of reagent strips 
dispensed for SMBG has increased, and almost all insulin-treated patients receive 
strips. While few diet-treated patients receive strips, they are more extensively 
dispensed to those treated with oral agents. Given that SMBG is no longer routinely 
recommended in non-insulin treated patients, strategies to reduce unnecessary 
dispensing of reagent strips are needed. 
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Introduction 
Self-monitoring of blood glucose (SMBG) is considered an integral part of treatment 
for people with type 1 diabetes, and those with type 2 diabetes who use insulin
1,2
. 
These patients can use SMBG readings to adjust insulin doses themselves, if 
appropriate, thereby assisting optimal glycaemic control. However, the benefits of 
SMBG among people with type 2 diabetes who do not use insulin are much less 
certain. Recent trials, reviews and meta-analyses have shown either no or very small 
effects of SMBG on glycaemic control
3,4,5
. Given that there is also concern over the 
high costs associated with SMBG
6
 and possible adverse psychological 
consequences
7,8
,  national guidelines state that routine monitoring is no longer 
recommended for patients who do not use insulin
9,10
, although it may benefit certain 
groups (eg users of sulponlyureas to reduce risk of hypoglycaemia)
1
.   
 
While the benefits of SMBG amongst non-insulin treated patients have been 
questioned, some (albeit limited) research suggests there has been a large increase in 
the numbers of patients who undertake SMBG. A UK survey in primary care found 
that over 80% of patients, including those treated with oral agents, did some 
monitoring, albeit this research involved a small self-selected patient group 
11
. 
Electronic prescribing records may provide a more objective picture of monitoring 
patterns, and a study using the General Practice Research Database (GPRD), indicated 
that prescriptions written for monitoring reagent strips among patients newly treated 
with oral agents increased from 19% to 32% between 1993 and 1998
12
. The most 
recent analysis used IMS-Mediplus data for 40,094 patients with type 2 diabetes from 
670 GP practices in the UK, and concluded that, in 2007, the proportion of patients 
treated with oral agents who self-monitored ranged from 36% to 58%, depending on 
the particular (combinations of) oral agents
13
. However, perhaps more surprisingly, 
the same proportion for patients treated by diet/exercise only was found to be as high 
as 26%.  
 
Given the recently published guidance that patients who do not use insulin should not 
routinely self-monitor
1
, alongside the limited and sometimes contradictory evidence 
currently available regarding monitoring patterns and frequency, we have carried out 
a study of the numbers and patterns of reagent strips for SMBG dispensed to patients 
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with type 2 diabetes in Tayside, Scotland, and compared results with those in 1993 
and 1999 to observe changes over time. 
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Patients and Methods 
The Health Informatics Centre, University of Dundee
14,15 
works on the record-linkage 
of health care data to facilitate epidemiological and health services research in the 
population of Tayside, Scotland (estimated population of 396,960 in 2008). Record-
linkage is enabled by the widespread use of a unique health care identifier (CHI 
number) that is allocated to people when they register with a General Practitioner 
(GP) in Scotland. SCI-DC (Scottish Care Information – Diabetes Collaboration) is a 
validated population-based diabetes information system in Tayside, compiled by 
record-linking several independent data sources (formerly known as DARTS: 
Diabetes Audit and Research in Tayside, Scotland)
14
. Detailed clinical information is 
available via SCI-DC for all patients with diabetes. The Medicines Monitoring Unit 
(MEMO) database
15
, developed for pharmacoepidemiological research, keeps 
computerised records of every prescription dispensed
 
to Tayside residents, including 
those for self-monitoring equipment. 
 
From SCI-DC, we obtained prevalence estimates in Tayside for people who had been 
diagnosed with type 2 diabetes: at any time in 1993 and 1999, and prior to January 1
st
 
2009. For every patient, we collated all prescriptions dispensed for blood reagent 
strips during the relevant calendar year. We were able to calculate the exact numbers 
of reagent strips dispensed for SMBG from details on the prescription. We record-
linked these data to clinical and demographic information. We then categorised 
patients into those who had also received any prescription for insulin during the year 
as insulin-treated, those who received prescriptions for oral agents only as oral-
treated, and the remaining patients as diet-treated. For the 2009 sample, we were also 
able to identify patients in the oral-treated group who had received any prescription 
for sulphonylureas. We investigated whether monitoring patterns were associated with 
age, sex and a postcode measure of social and material deprivation (SIMD) that 
classified people into quintiles of deprivation. This incorporates information on 
income, employment, health and disability, education, skills and training, and access 
to services, for small geographical areas
16
. To explore factors associated with whether 
or not a patient was dispensed reagent strips for any SMBG, we used logistic 
regression analysis to obtain adjusted odds ratios (with 95% confidence intervals) for 
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these explanatory variables independently. Given there were only three variables, we 
entered all three into the model simultaneously.  
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Results 
In 1993, 219,376 reagent strips for blood glucose monitoring were dispensed to 
patients with type 2 diabetes in Tayside, compared with 1,058,384 in 1999 and 
1,777,664 in 2009. These were dispensed to 5,728 and 8,109 patients in 1993 and 
1999 respectively, and 16,450 patients who had type 2 diabetes on 1
st
 January 2009. 
Overall, the proportions of people who were dispensed any reagent strips for SMBG 
increased from 15.5% in 1993, to 24.2% in 1999 to 29.8% in 2009.  
 
Table 1 shows that the largest increase in reagent strips dispensed for SMBG occurred 
among people treated with oral agents. While the proportion of diet-treated patients 
who were dispensed reagent strips was still very low in 2009 (5.6%), the proportion 
for those treated with oral agents tripled from 9.4% to 27.4% during this time. The 
majority of patients treated with insulin received reagent strips for SMBG; this 
proportion is now over 90%. Among patients who received any reagent strips, the 
total numbers of strips dispensed also increased among patients treated with oral 
agents and insulin over the study period. The mean number of strips dispensed among 
insulin-treated patients is sufficient for daily monitoring. For those treated with oral 
agents, sufficient strips are dispensed for monitoring 3-4 times weekly. The 
proportion monitoring and the mean number of strips dispensed were higher among 
patients who were treated with sulphonylureas. However, there was still one fifth of 
patients treated with metformin and other oral agents who were receiving reagent 
strips for SMBG.  
 
Table 2 shows that receiving reagent strips for SMBG among patients not treated with 
insulin is more common among women and less deprived groups, but decreases with 
increasing age, with the odds ratios indicating independent effects of each of these 
factors.  The associations are particularly evident for patients treated with oral agents.   
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Discussion 
This study has confirmed a general increase in reagent strips dispensed for SMBG 
among all patients with type 2 diabetes over the past 15 years.  While it is encouraging 
that over 90% of insulin-treated patients receive reagent strips, and obtain sufficient 
numbers to monitor daily, the increase in non insulin treated patients receiving reagent 
strips may be cause for concern, particularly among patients treated with oral agents.  
 
This study measured the number of reagent strips that were dispensed to patients in 
community pharmacies. Although we cannot be sure whether patients actually used 
all the strips that were dispensed to them, and they may also have received strips from 
other sources, the study has identified clear trends over time. We also consider that 
dispensed prescribing records for an entire diabetic population may provide a more 
objective measure of actual monitoring behaviour than self-report from selected 
samples of patients. Nevertheless the finding that only 5.6% of diet-treated patients 
received reagent strips for SMBG stands in stark contrast to the 26% reported using 
electronic IMS-Mediplus data from 670 GP practices
13
. That study used QoF data 
(Quality and Outcomes Framework) to locate patients with diabetes, hence it was able 
to identify only those who were receiving active treatment and monitoring. In 
contrast, the SCI-DC diabetes register in Tayside record-links information from 
several independent data sources and has high sensitivity and specificity for 
identifying all patients with diabetes
14
.  Not only is the IMS-Mediplus study likely to 
have under-ascertained diet treated patients, patients who monitored were, by 
definition, more likely to have been identified. We therefore consider that our figure 
of 5.6% is a more realistic estimate of the prevalence of patients with type 2 diabetes 
who receive reagent strips for SMBG but who are not treated with oral agents or 
insulin.  
 
The greatest increase in reagent strips dispensed for SMBG was observed in patients 
treated with oral agents, with 27.4% receiving strips in 2009. The mean number of 
strips per patient would enable monitoring 3-4 times per week. In some practices in 
Scotland, GPs are no longer writing prescriptions for reagent strips for such patients, 
and it may be that this figure has decreased slightly since 2009.  However, although 
this figure is also lower than in the IMS-Mediplus study, probably for the reasons 
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already discussed, it is still substantial, given that routine monitoring is not 
recommended
1
. While the SIGN guidelines specify certain groups who may benefit 
from monitoring
1
, for example patients using sulphonylureas who are at high risk of 
hypoglycaemia, this is unlikely to apply to over one third of these patients.   
 
In summary, given the recent introduction of guidelines recommending that people 
who are not treated with insulin do not routinely undertake SMBG, alongside 
increased rationing of monitoring strips, the challenge is to identify patients for whom 
carrying out monitoring is unlikely to be beneficial and to dissuade them from doing 
so. Although we have identified several factors associated with receiving increased 
numbers of reagent strips for SMBG; specifically, being younger, female and from a 
less deprived area, it is not clear whether this arises from patient and/or prescriber 
expectations or behaviours. The increasing variety, availability and ease of use of self-
monitoring testing kits, alongside marketing by their manufacturers, may be fuelling 
patient demand. To reduce unnecessary levels of monitoring, further research is 
therefore needed drawing upon patients’ and health professionals’ understandings, 
motivation and experience of monitoring, particularly among those patients who 
monitor most frequently.  
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Tables 
 
 No. of 
patients  
Nos. of patients who 
received reagent strips 
for SMBG 
Mean no. of strips 
dispensed per 
patient over 12 
month period 
(mean in patients  
who received any 
strips)  
1993 
Diet  2,240 57 (2.5%) 4.1 (160.2) 
Oral  2,652 250 (9.4%) 13.3  (140.7) 
Insulin 836 557 (66.6%) 195.5 (293.5) 
All  5,728 864 (15.5%) 36.3 (240.5) 
1999 
Diet 2,598 88 (3.4%) 5.0 (148.3) 
Oral  4,203 716 (17.0%) 29.0 (170.3) 
Insulin 1,308 1,099 (84.0%) 349.1 (415.5) 
All 8,109 1,903 (23.5%) 73.0 (310.9) 
2009 
Diet 5,167 289 (5.6%) 8.4 (150.6)  
Oral 
 Any sulph 
 No sulph 
 
8,856 
 4,518 
 4,338 
 
2,427 (27.4%) 
 1,513 (33.5%) 
 914 (21.2%) 
54.4 (198.3) 
 70.6 (210.8) 
 37.4 (177.8) 
Insulin 2,427 2,186 (90.1%)  516.2 (573.1) 
All  16,450 4,902 (29.8%)  362.6 (362.3) 
 
Table 1: Numbers of patients receiving reagent strips for SMBG, and mean numbers 
of reagent strips dispensed in 1993, 1999 and 2009.  
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 Diet-treated Treated with oral agents  
 Total Total 
monitoring 
(%) 
Adj. OR 
(95% CI) 
Total Total 
monitoring 
(%) 
Adj. OR 
(95% CI) 
Sex 
Male 2,582 148 (5.7%)  1.00 4,939 1,330 
(26.9%) 
1.00 
Female 2,296 141 (6.1%)  1.13  
(0.89-1.44)  
3,917 1,097 
(28.0%) 
1.12  
(1.02–1.23) 
Age 
< 45 yrs 299 17 (5.7%)  1.00 525 180 
(34.3%)  
1.00 
45-54 yrs 590 30 (5.1%)  0.89  
(0.48-1.63)  
1,283 393 
(30.6%) 
0.82  
(0.66–1.02) 
55–64 yrs 1,131 84 (7.4%)  1.23  
(0.72-2.12) 
2,287 654 
(28.6%) 
0.73  
(0.59-0.89) 
65-74 yrs 1,388 87 (6.3%) 1.04 
(0.61-1.78) 
2,691 763 
(28.4%) 
0.71  
(0.58-0.87) 
75+ yrs 1,470 71 (4.8%)  0.78  
(0.48-1.35) 
2,070 437 
(21.1%) 
0.47  
(0.38-0.58)  
Deprivation (quintiles)  
1 (most 
deprived) 
792 29 (3.7%)  1.00 1,527 348 
(22.8%) 
1.00 
2 862 38 (4.4%)  1.22  
(0.74–1.99)  
1,585 388 
(24.5%) 
1.12  
(0.95-1.33) 
3 856 58 (6.8%)  1.87 
(1.18-2.95) 
1,670 496 
(29.7%) 
1.50  
(1.28-1.77) 
4 1,515 103 (6.8%)  1.88 
(1.23–2.86) 
2,605 772 
(29.6%) 
1.53  
(1.32-1.77) 
5 (least 
deprived) 
794 56 (7.1%) 1.95 
(1.23–3.09) 
1,358 388 
(28.6%) 
1.47  
(1.24-1.74) 
Not known 59 5 (8.5%)  2.32 
(0.86–6.22) 
111 35 
(31.5%) 
1.55  
(1.02-2.35)  
 
 15 
Table 2: Results of logistic regression to evaluate effects of age, sex and deprivation 
on whether patients received any SMBG reagent strips in 1999, stratified by treatment 
type   
